SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001829126-24-003401
Filing Date
2024-05-15
Accepted
2024-05-15 16:15:53
Documents
46
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q titanpharma_10q.htm   iXBRL 10-Q 475222
2 EXHIBIT 31.1 titanpharma_ex31-1.htm EX-31.1 10934
3 EXHIBIT 32.1 titanpharma_ex32-1.htm EX-32.1 4554
  Complete submission text file 0001829126-24-003401.txt   2526658

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ttnp-20240331.xsd EX-101.SCH 21488
5 XBRL CALCULATION FILE ttnp-20240331_cal.xml EX-101.CAL 29803
6 XBRL DEFINITION FILE ttnp-20240331_def.xml EX-101.DEF 59094
7 XBRL LABEL FILE ttnp-20240331_lab.xml EX-101.LAB 173843
8 XBRL PRESENTATION FILE ttnp-20240331_pre.xml EX-101.PRE 135810
49 EXTRACTED XBRL INSTANCE DOCUMENT titanpharma_10q_htm.xml XML 270877
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

IRS No.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-13341 | Film No.: 24950973
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)